NCT06087055View on ClinicalTrials.gov

Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 12, 2023

Primary Completion Date

June 5, 2023

Study Completion Date

August 7, 2023

Conditions
Healthy Participant
Interventions
DRUG

GST-HG171/Ritonavir

Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3

DRUG

Itraconazole

Administered orally once daily for 9 days from Days 8 through 16

DRUG

GST-HG171/Ritonavir

Administered orally BID for 3 day for a total on 5 doses starting on Day 12 through Day 14

Trial Locations (1)

Unknown

The first hospital of Jilin University, Changchun

All Listed Sponsors
lead

Fujian Akeylink Biotechnology Co., Ltd.

INDUSTRY

NCT06087055 - Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants | Biotech Hunter | Biotech Hunter